Vertex Pharmaceuticals Incorporated (LON:0QZU)
London · Delayed Price · Currency is GBP · Price in USD | Market Cap | 85.46B |
| Revenue (ttm) | 8.72B |
| Net Income (ttm) | 2.73B |
| Shares Out | n/a |
| EPS (ttm) | 10.58 |
| PE Ratio | 31.26 |
| Forward PE | 22.20 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 133 |
| Average Volume | 526 |
| Open | 453.50 |
| Previous Close | 454.33 |
| Day's Range | 451.50 - 456.19 |
| 52-Week Range | 362.50 - 519.68 |
| Beta | 0.32 |
| RSI | 57.81 |
| Earnings Date | Feb 2, 2026 |
About Vertex Pharmaceuticals
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The com... [Read more]
News
Vertex Pharmaceuticals (VRTX) Dips More Than Broader Market: What You Should Know
In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $453.74, marking a -1.31% move from the previous day.
Here's Why Vertex Pharmaceuticals (VRTX) is a Strong Momentum Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
2 Growth Stocks to Buy For 2026 and Beyond
Vertex could have several catalysts in 2026, helping it set a strong foundation for the future. DexCom is expanding its addressable market in order to help deal with some current challenges.
Vertex Pharmaceuticals (VRTX) Target Price Raised to $525 by Leerink Partners | VRTX Stock News
Vertex Pharmaceuticals (VRTX) Target Price Raised to $525 by Leerink Partners | VRTX Stock News
3 Supercharged Growth Stocks to Buy and Hold Into the 2030s
Amazon's profitability underscores the success of established and emerging growth sources. Vertex Pharmaceuticals is launching several new products, and more approvals could be around the corner.
Forget Moderna Stock, This is a Much Better Buy
Moderna stock soared in the early stages of the pandemic, then struggled -- but in recent times, it's been on the rise. This other biotech has proven itself as a long-term winner.
Vertex Pharmaceuticals Incorporated (VRTX) Is a Trending Stock: Facts to Know Before Betting on It
Recently, Zacks.com users have been paying close attention to Vertex (VRTX). This makes it worthwhile to examine what the stock has in store.
Vertex to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 12
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Dr. Reshma Kewalramani, Chief Executive Officer and President, will present at the 44th Annual J.P. Mor...
Best Defensive Stocks To Balance Tech Sector Volatility
December's mixed performance for tech may be an early signal that leadership is narrowing, especially among the value-stretched stocks. Investors looking forward to 2026 may find better risk-adjusted ...
Vertex Pharmaceuticals (VRTX) Registers a Bigger Fall Than the Market: Important Facts to Note
In the closing of the recent trading day, Vertex Pharmaceuticals (VRTX) stood at $449.52, denoting a -1.2% move from the preceding trading day.
SCHX, TJX, LOW, VRTX: Large Inflows Detected at ETF
Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the Schwab US Large-Cap ETF (Symbol: SCHX) where we have detected an appro...
Harbor Capital Appreciation Fund Q3 2025 Portfolio Review
Microsoft shares underperformed due to concerns about its relationship with OpenAI following the Oracle/OpenAI deal announcement. Vertex Pharmaceuticals lost value following disappointing clinical tri...
12 Days of Investing: My Top 12 Stocks to Buy Before 2026
There are only 12 investing days left in 2025. Now is a great time to load up on stocks that may win next year -- and over time.
What's Driving the Market Sentiment Around Vertex Pharmaceuticals Inc?
Vertex Pharmaceuticals Inc's (NYSE: VRTX) short interest as a percent of float has risen 11.24% since its last report. According to exchange reported data, there are now 4.46 million shares sold shor...
2 Healthcare Stocks to Buy Ahead of the New Year
CRISPR Therapeutics could soar on the back of significant pipeline progress next year. Vertex's slow and steady approach to diversifying its lineup should eventually pay off.
Investors Heavily Search Vertex Pharmaceuticals Incorporated (VRTX): Here is What You Need to Know
Vertex (VRTX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
3 Brilliant Growth Stocks to Buy Now and Hold for the Long Term
Apple's fiercely loyal customer base gives it a built-in market for any new devices it might launch in the future. MercadoLibre is positioned to grow rapidly in the Latin America e-commerce and fintec...
VRTX: Wells Fargo Raises Price Target to $515, Maintains Overweight Rating | VRTX Stock News
VRTX: Wells Fargo Raises Price Target to $515, Maintains Overweight Rating | VRTX Stock News
Vertex's Gene Therapy Works In Children With Blood Disorders
Vertex Pharmaceuticals presents clinical data demonstrating ... Full story available on Benzinga.com
Vertex Pharmaceuticals (VRTX) Reveals Promising CASGEVY Data for Young Patients
Vertex Pharmaceuticals (VRTX) Reveals Promising CASGEVY Data for Young Patients
Down 10%, Should You Buy the Dip on Vertex Pharmaceuticals?
The stock has fallen from a peak back in April.
Vertex Presents New CASGEVY Data Highlighting Benefits In Children Ages 5-11
(RTTNews) - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced new data from pivotal studies of CASGEVY (exagamglogene autotemcel), demonstrating the transformative potential of the therapy ...
Vertex's gene therapy shows promise in younger children with blood disorders
Vertex Pharmaceuticals said on Saturday its gene therapy helped children aged between 5 and 11 years with sickle cell disease to be free of painful events and allowed those with another blood disorder...
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in peo...
Insider Sell: WAGNER CHARLES F JR Sells 14,000 Shares of Vertex Pharmaceuticals Inc (VRTX)
Insider Sell: WAGNER CHARLES F JR Sells 14,000 Shares of Vertex Pharmaceuticals Inc (VRTX)